Vertex Pharma (VRTX) Tops Q3 EPS by 48c, Lifts FY Guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $508.98 -2.54%
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +8.4%
Financial Fact:
Cost of product revenues: 53.22M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $3.56, $0.48 better than the analyst estimate of $3.08. Revenue for the quarter came in at $1.98 billion versus the consensus estimate of $1.86 billion.
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $7.4-7.5 billion, versus the consensus of $7.32 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
- Morgan Stanley upgrades Ivanhoe Mines, cuts Alcoa and Vale on metals outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
